Evaluation of MRI accuracy after primary systemic therapy in breast cancer patients considering tumor biology: optimizing the surgical planning
By:
References
- Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-85. 10.1158/1078-0432.CCR-04-2421
- Yersal O, Barutca S. Biological subtypes of breast cancer: prognostic and therapeutic implications. World J Clin Oncol 2014; 5: 412-24. 10.5306/wjco.v5.i3.412
- Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 J Natl Cancer Inst Monogr 2001; 30: 96-102. PMID: 11773300
- Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Lluch A, et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methrotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol 2009; 27: 2474-81. 10.1200/JCO.2008.19.2567
- Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer 2011; 47: 2084-90. 10.1016/j.ejca.2011.06.014
- Murphy BL, Day CN, Hoskin TL, Habermann EB, Boughey JC. Neoadjuvant chemotherapy use in breast cancer is greatest in excellent responsers: triple-negative and HER2+ subtypes. Ann Surg Oncol 2018; 25: 2241-8. 10.1245/s10434-018-6531-5
- Boughey J, McCall L, Ballman K, Mittendorf EA, Ahrendt GM, Wilke LG, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer. Ann Surg 2014; 260: 608-16. 10.1097/SLA.0000000000000924
- von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796-804. 10.1200/JCO.2011.38.8595
- Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384: 164-72. 10.1016/S0140-6736(13)62422-8
- Boughey JC, Ballman KV, McCall LM, Mittendorf EA, Symmans WF, Julian TB, et al. Tumor biology and response to chemotherapy impact breast cancer-specific survival in node-positive breast cancer patients treated with neoadjuvant chemotherapy: long-term follow-up from ACOSOG Z1071 (Alliance). Ann Surg 2017; 266: 667-76. 10.1097/SLA.0000000000002373
- Dialani V, Chadashvili T, Slanetz PJ. Role of imaging in neoadjuvant therapy for breast cancer. Ann Surg Oncol 2015; 22: 1416-24. 10.1245/s10434-015-4403-9
- Straver ME, Loo CE, Rutgers EJ, Oldenburg HS, Wesseling J, Vrancken Peeters MJ, et al. MRI model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy. Ann Surg 2010; 251: 701-7. 10.1097/SLA.0b013e3181c5dda3
- De los Santos J, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, et al. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer 2013; 119: 1776-83. 10.1002/cncr.27995
- McGuire KP, Toro-Burguete J, Dang H, Young J, Soran A, Zuley M, et al. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy? Ann Surg Oncol 2011; 18: 3149-54. 10.1245/s10434-011-1912-z
- Fukuda T, Horii R, Gomi N, Miyagi Y, Takahashi S, Ito Y, et al. Accuracy of magnetic resonance imaging for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy: association with breast cancer subtype. Springerplus 2016; 5: 152. 10.1186/s40064-016-1800-x
- Bouzón A, Acea B, Soler R, Iglesias Á, Santiago P, Mosquera J, et al. Diagnostic accuracy of MRI to evaluate tomour response and residual tumour size after neoadjuvant chemotherapy in breast cancer patients Radiol Oncol 2016; 50: 73-9. 10.1515/raon-2016-0007
- Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Ann Oncol 2013; 24: 2206-23. 10.1093/annonc/mdt303
- Rosen EL, Blackwell KL, Baker JA, Soo MS, Bentley RC, Yu D, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. Am J Roentgenol 2003; 181: 1275-82. 10.2214/ajr.181.5.1811275
- Yeh E, Slanetz P, Kopans DB, Rafferty E, Georgian-Smith D, Moy L, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. Am J Roentgenol 2005; 184: 868-77. 10.2214/ajr.184.3.01840868
- Croshaw R, Shapiro-Wright H, Svensson E, Erb K, Julian T. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients. Ann Surg Oncol 2011; 18: 3160-3. 10.1245/s10434-011-1919-5
- Orel S. Who should have breast magnetic resonance imaging evaluation? J Clin Oncol 2008; 26: 703-11. 10.1200/JCO.2007.14.3594
- Eom HJ, Cha JH, Choi WJ, Chae EY, Shin HJ, Kim HH. Predictive clinicopathologic and dynamic contrast-enhanced MRI findings for tumor response to neoadjuvant chemotherapy in triple-negative breast cancer. Am J Roentgenol 2017; 208: 225-30. 10.2214/AJR.16.17125
- Wang J, Buchholz TA, Middleton L, Allred DC, Tucker SL, Kuerer HM, et al. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. Cancer 2002; 94: 3107-14. 10.1002/cncr.10585
- Goorts B, van Nijnatten TJ, de Munck L, Moossdorff M, Heuts EM, de Boer M, et al. Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat 2017; 163: 83-91. 10.1007/s10549-017-4155-2
- Bahri S, Chen JH, Mehta RS, Carpenter PM, Nie K, Kwon SY, et al. Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol 2009; 16: 1619-28. 10.1245/s10434-009-0441-5
- Ko ES, Han BK, Kim RB, Ko EY, Shin JH, Hahn SY, et al. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer. Ann Surg Oncol 2013; 20: 2562-8. 10.1245/s10434-013-2925-6
- Moon H-G, Han W, Ahn SK, Cho N, Moon WK, Im SA, et al. Breast cancer molecular phenotype and the use of HER2-targeted agents influence the accuracy of breast MRI after neoadjuvant chemotherapy. Ann Surg 2013; 257: 133-7. doi:10.1097/SLA.0b013e3182686bd9
- Patel BK, Hilal T, Covington M, Zhang N, Kosiorek HE, Lobbes M, et al. Contrast-enhanced spectral mammography is comparable to MRI in the assessement of residual breast cancer following neoadjuvant systemic therapy. Ann Surg Oncol 2018; 25: 1350-6. 10.1245/s10434-018-6413-x
- Rauch GM, Kuerer HM, Adrada B, Santiago L, Moseley T, Candelaria RP, et al. Biopsy feasibility trial for breast cancer pathologic complete response detection after neoadjuvant chemotherapy: imaging assessment and correlation endpoints. Ann Surg Oncol 2018; 25: 1953-60. doi:10.1245/s10434-018-6481-y
- Heldahl MG, Lundgren S, Jensen LR, Gribbestad IS, Bathen TF. Monitoring neoadjuvant chemotherapy in breast cancer patients: improved MR assessment at 3 T? J Magn Reson Imaging 2011; 34: 547-56. 10.1002/jmri.22642
Language: English
Page range: 171 - 177
Submitted on: Dec 25, 2018
Accepted on: Apr 18, 2019
Published on: May 8, 2019
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2019 Alberto Bouzón, Ángela Iglesias, Benigno Acea, Cristina Mosquera, Paz Santiago, Joaquín Mosquera, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.